Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17788538 | 0.85 | DPP4 (0.37) | ARG1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20671832 | 0.82 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL20671901 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL24322589 | 0.76 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL19738913 | 0.70 | KMT2A (0.39) | ARG1ALDH1A1HPGDCYP2C19 | |
| SCHEMBL22541779 | 0.69 | ARG1 (0.40) | ARG1CYP2C19 | |
| SCHEMBL25036349 | 0.67 | ARG1 (0.37) | ARG1ALDH1A1CYP2C19 | |
| SCHEMBL25738639 | 0.66 | ARG1 (0.38) | ARG1 | |
| SCHEMBL17177242 | 0.66 | ARG1 (0.39) | ARG1ALDH1A1 | |
| SCHEMBL24412190 | 0.65 | ARG1 (0.38) | ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2014210159-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | CFTR, HSP90B1, SERPINB1 | ARG1 3212/4885SMN1; SMN2 1740/4885ALDH1A1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.